Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $50.4 billion.

  • Takeda Pharmaceutical's Total Liabilities fell 24.1% to $50.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $50.4 billion, marking a year-over-year decrease of 24.1%. This contributed to the annual value of $48.0 billion for FY2025, which is 1163.83% down from last year.
  • Takeda Pharmaceutical's Total Liabilities amounted to $50.4 billion in Q4 2025, which was down 24.1% from $49.8 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Total Liabilities high stood at $73.1 billion for Q1 2021, and its period low was $47.9 billion during Q1 2025.
  • Over the past 5 years, Takeda Pharmaceutical's median Total Liabilities value was $54.1 billion (recorded in 2023), while the average stood at $56.5 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Total Liabilities crashed by 1995.99% in 2022, and later fell by 7.63% in 2024.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Total Liabilities stood at $64.8 billion in 2021, then fell by 19.96% to $51.9 billion in 2022, then decreased by 2.44% to $50.6 billion in 2023, then fell by 0.08% to $50.6 billion in 2024, then fell by 0.24% to $50.4 billion in 2025.
  • Its last three reported values are $50.4 billion in Q4 2025, $49.8 billion for Q3 2025, and $49.3 billion during Q2 2025.